NCT05438342

An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 195 (estimated)
• Sponsor: Shanghai Pudong Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The clinical efficacy of chemotherapy /PD-1 monoclonal antibody/targeted therapy, chemotherapy /PD-1 monoclonal antibody/targeted therapy + noninvasive electromagnetic wave hyperthermia and chemotherapy /PD-1 monoclonal antibody/targeted therapy + noninvasive electromagnetic wave hyperthermia + autosomatic immunotherapy in the treatment of refractory refractory solid tumors with first-line treatment failure was compared.

Conditions

• Advanced Cancer
• Metastatic Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Autologous Adoptive immune cells	Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
DEVICE	Thermotron RF-8EX	Hyperthermia for 40-50 minutes
DRUG	Chemotherapy，checkpoint immunotherapy, targeted therapy	The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines

Timeline

• Start date: 2021-11-01
• Primary completion: 2023-10-01
• Completion: 2023-10-31
• First posted: 2022-06-29
• Last updated: 2022-06-29

Locations

1 site across 1 country: China